Pemvidutide

researchMetabolic/Weight

Evidence grade

DResearch/compounded/adjunct (no established FDA indication)

Cardiovascular · 0–5 · separate axis

PurposeMetabolic / Weight

MechanismGLP-1 and glucagon dual agonist in development for obesity and MASH

EffectsStudied for weight loss with a stated emphasis on preserving lean mass

DosingNo human dose established.

Bottom linePopular in research/compounding; human safety/benefit not well-established.

Batches on filenone

No tested batches on file.

Read with10

Cautions & interactions

Not FDA-approved; avoid self-administration; unverified sourcing and purity

No well-established interaction profile for non-approved peptides; avoid combining multiple research compounds; discuss meds with clinician.

CV 1 of 5 — No solid direct cardiovascular outcomes evidence; any benefit is indirect or unproven.